BetaSite sustained release formulation of the beta blocker levobunolol data

The Alameda, Calif., company announced positive Phase III results, testing doses of 0.1 percent or 0.5 percent

Read the full 172 word article

How to gain access

Continue reading with a
two-week free trial.